This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Biotech Stock Mailbag: Amicus, Amarin, Oncothyreon

Stocks in this article: FOLD ONTY AMRN

That leaves Oncothyreon with the experimental cancer drug PX-866, a PI-3K inhibitor. PI-3K is a sexy molecular target right now but more so in hematological cancer than solid tumors. To date, all the clinical work with PX-866 is in solid tumors. Results from randomized phase II studies in non-small cell lung cancer and metastatic colon cancer are expected in the first and second quarters of 2013.

We'll see what those data tell us about PX-866 soon enough.

Not all PI-3K inhibitors are the same. Right now, the buzz enveloping Gilead Sciences' (GILD) idelasib, Infinity Pharmaceuticals' (INFI) IPI-145 and Pharmacyclics' (PCYC) ibrutinib (a closely related BTK inhibitor) has not spread to PX-866.

Paul T. writes, "I'm interested in knowing more about websites and other sources of information for deeper knowledge in biotech stocks and investing. What are your favorites ways to do research? Thanks."

Great question. Here's a list of my favorite biotech-related websites and resources. Some of these I use almost daily, others less frequently. Take a look and figure out what works best for you.

The basics, all free services:

The SEC's website for access to regulatory filings. Indispensable. You have to read a company's 10-Qs, 10-Ks and 8-Ks, always.

I use Yahoo! Finance for basic stock price and related information, plus access to press releases. My web browser's home page is a customized MyYahoo! page with real-time stock quotes and biotech and drug industry news. Stock traders likely have more sophisticated setups but MyYahoo! has always worked well for me. for keeping tabs on ongoing clinical trials.

Get to know your way around the FDA's website. For specific drug information, including approved drug labels, use the search engine at Drugs@FDA. The FDA also maintains a page for advisory panel information, which is helpful.

PubMed for looking up publishing clinical studies and research papers. I've also had good luck with Google Scholar.

StockTwits: Like it or not, Twitter is an entrenched part of Wall Street these days, certainly for active investors and traders. I'm particularly fond of StockTwits' "Signals" tools like sector heatmaps. I check the health-care heatmap every day to see which biotech stocks are capturing the most social media buzz. On a related note, check out Appeering for curated Twitter conversation threads. They do a great job of capturing much of the biotech talk that passes through Twitter.

3 of 4

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,060.01 +6.30 0.03%
S&P 500 2,093.11 +4.34 0.21%
NASDAQ 4,811.7450 +4.8860 0.10%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs